( en | de | ru )

 

Disambiguation

From post

копироватьудалитьдобавить публикацию в буфер
First-in-human clinical trials with vaccines-what regulators want.

, , и . Nat Biotechnol, 28 (9): 910-916 (2010)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed.

C Schneider

Harun K l ç

Refika K l ç

Rita C -K Chin

Ay K l ç

 

Другие публикации лиц с тем же именем

Maintaining `standards' for biosimilar monoclonal antibodies, , , , , и . Nat Biotechnol, 39 (3): 276-280 (марта 2021)Deciphering the EU clinical trials regulation, и . Nat Biotechnol, 34 (3): 231-233 (2016)Regulatorische Aspekte zu Biosimilars: Mythen und Fakten, и . Z Rheumatol, 74 (8): 695-700 (2015)Toward experimental assessment of receptor occupancy: TGN1412 revisited, , , , , , , и . J Allergy Clin Immunol, 122 (5): 890-892 (2008)How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations, и . N Biotechnol, 25 (5): 280-286 (2009)After the TGN1412 incident. Principles for assessment of first-in-man trials with monoclonal antibodies by the Paul Ehrlich Institute, и . Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 50 (10): 1213-1220 (2007)Toward biosimilar monoclonal antibodies, и . Nat Biotechnol, 26 (9): 985-990 Review (2008)Clinical development of advanced therapy medicinal products in europe: evidence that regulators must be proactive, , , , и . Mol Ther, 20 (3): 479-482 (2012)Development and regulation of biosimilars: current status and future challenges, , и . BioDrugs, 27 (3): 203-211 (2013)Taking immunogenicity assessment of therapeutic proteins to the next level., , , , , , , , , и 14 other автор(ы). Biologicals, 39 (2): 100-109 (2011)